

Efficacy & Safety of LOBO™ Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations

NCT06735976

Status	RECRUITING
Phase	Not Applicable
Sponsor	University of North Carolina, Chapel Hill
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (4)

- At least 1 PAVM with a feeding artery ≥ 2 mm in diameter and a feeding artery amenable to the use of LOBO™ device (i.e. feeding artery length of ≥ 1 cm). Given the length of embolic devices including LOBO™, the proximal vessel length to the PAVM sac must be of sufficient size for embolization to be feasible. If patients have at least 1 PAVM where the feeding artery length is ≥ 1 cm, they are eligible for enrollment.
- Patients with multiple PAVMs meeting eligibility criteria may be enrolled with the intent of embolizing multiple different PAVMs with the LOBO™ device in the same embolization session or in separate sessions.
- Estimated Glomerular Filtration Rate ≥ 30 ml/min
- Per standard of care (SOC), all pregnant women to be enrolled must be in their 2nd or 3rd trimesters

Exclusion (4)

- Confounding bleeding disorders other than HHT
- Life-threatening iodinated contrast allergy not amenable to prophylactic therapy with steroids
- Underlying coagulopathy
- Patients on anti-platelets or anti-coagulation medications

Locations (1 total)

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States